Free  Covid-19 vaccines: good for business too

Marketing Authorisations

Olaparib (Lynparza°) in combination with bevacizumab in ovarian cancer

Inset. Olaparib monotherapy in ovarian cancer after at least two lines of chemotherapy

Atezolizumab (Tecentriq°) + bevacizumab in certain hepatocellular carcinomas

Lumasiran (Oxlumo°) in primary hyperoxaluria type 1

Sofosbuvir (Sovaldi°), sofosbuvir + ledipasvir (Harvoni°) in chronic hepatitis C from 3 years of age

Sofosbuvir + velpatasvir (Epclusa°) in chronic hepatitis C in children from 6 years of age and in adolescents

Budesonide (Jorveza°) orodispersible tablets in eosinophilic oesophagitis

Ixekizumab (Taltz°) in axial spondyloarthritis

Upadacitinib (Rinvoq°) in "radiographic" axial spondyloarthritis

Secukinumab (Cosentyx°) in "non-radiographic" axial spondyloarthritis

Nasal naloxone 1.8 mg (Nyxoid°) in opioid overdose

Free  Rituximab (Mabthera° or other brands) in certain non-Hodgkin lymphomas in children

Adverse Effects

Update on myocarditis linked to the covid-19 messenger RNA vaccines tozinameran (Comirnaty°) and elasomeran (Spikevax°)

Flecainide: fatalities and cardiac arrests?

Immunostimulatory immune checkpoint inhibitors: toxic epidermal necrolysis and Stevens-Johnson syndrome

Pneumococcal vaccine errors: infants poorly protected

INN Common stem: ­-gliflozin

Outlook

Free  Towards better patient care: drugs to avoid in 2022

Inset. Main changes in the 2022 update

The need for double-blind randomised clinical trials in oncology

Conflicts of interest: insufficient transparency in Europe

A new European authority for health crises

Masthead

Free  Masthead